Zivo Bioscience Shareholders Approve Directors, Accountant, and Executive Compensation
Shareholders of Zivo Bioscience, Inc. gathered at the annual meeting on June 9, 2025, where they voted to approve the election of two Class III directors, the reappointment of BDO USA, P.C. as the company's independent registered public accounting firm, and the compensation of the company's named executive officers. The proposals were detailed in the company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025.
Key Takeaways:
- Shareholders approved the election of John B. Payne and Alison A. Cornell as Class III directors, each to serve a three-year term until the 2028 annual meeting.
- The approval was based on a total of 2,507,058 shares of common stock present at the meeting, representing approximately 66.11% of the shares outstanding as of the record date.
- BDO USA, P.C. was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Shareholders also approved the compensation of the company's named executive officers on an advisory basis.
- The final vote results showed that Proposal 1 passed with 1,681,190 votes for and 32,957 votes withheld.
- Proposal 2 passed with 2,438,089 votes for and 53,549 votes against, and 15,420 abstentions.
- Proposal 3 passed with 1,665,583 votes for and 48,443 votes against, with 121 abstentions and 792,911 broker non-votes.
Statistics:
- 2,507,058 shares of common stock were present at the meeting, representing approximately 66.11% of the shares outstanding.
- 1,681,190 votes were cast for Proposal 1, with 32,957 votes withheld.
- 2,438,089 votes were cast for Proposal 2, with 53,549 votes against, and 15,420 abstentions.
- 1,665,583 votes were cast for Proposal 3, with 48,443 votes against, 121 abstentions, and 792,911 broker non-votes.
Sources:
- ZIVO BIOSCIENCE, INC. (2025, June 11). FORM 8-K CURRENT REPORT. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549